Leading MNC Pharma Stock is in focus after it posted its Q3 Results with Robust Net Profit Growth and strong growth in its Vaccine & Medicine Segments.
Share Price Movement
With a market capitalization of Rs. 40,742 Crore, the stock of GlaxoSmithKline Pharmaceuticals ( GSK Pharma ) opened at Rs. 2199.95 up 9.01 percent from yesterday’s closing price of Rs. 2018, and later it hit the upper circuit of 20 percent at Rs. 2,421.60
Q3FY25 Results
The company reported a 17.03 percent YoY increase in revenue from Rs. 805.26 Crore in Q3FY24 to Rs. 949.42 Crore in Q3FY25. On a QoQ basis, the company reported a decrease of 6.06 percent in revenue from Rs. 1010.77 Crore in the previous quarter.
Their Net profit saw an impressive increase of 402.79 percent YoY from Rs. 45.72 Crore to Rs. 229.88 Crore for the same period. On a QoQ basis, the company reported an increase of 8.95 percent in Net profit from Rs. 252.5 Crore in the previous quarter.
Also read: PSU stock in focus after it plans to invest ₹84,000 Cr for 20-GW pumped storage capacity
Operational Highlights
Strong performance across General Medicine flagship brands led by Augmentin, Ceftum, and Tbact with overall underlying growth of +11% driven by volumes. And the Paed Vaccines portfolio delivered +15% growth led by Boostrix, Infanrix Hexa & Varilrix.
EBITDA improved through a better gross margin mix, improved productivity, and cost efficiencies and PAT stepped up due to stable gross margin, realignment of resources & cost management initiatives.
About the Company
GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) is the Indian subsidiary of the global pharmaceutical company GSK plc, established in 1924. It offers a wide range of prescription medicines and vaccines across multiple therapeutic areas, including respiratory, dermatology, oncology, and cardiovascular diseases. The company is actively expanding its global presence and has entered into partnerships to strengthen its drug development pipeline.
Written By Abhishek Das
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
